The GROWTH consortium, funded by the European Commission (2019-2023), is made up to train a new generation of researchers working on new pathological insights, biomarker diagnostics and personalized nutritional interventions for intestinal failure in neonates and preterm infants.
Academic and industry partners, covering various disciplines ranging from fundamental research to clinical paediatrics and analytical chemistry to organoid and gut-on-chip applications, have teamed up in the European Union.
GROWTH aims to set-up a new European platform that trains young scientists in the industry-led exploration of innovative routes to fully exploit the potential of early life nutrition to prevent inflammatory disease. GROWTH coordinates 8 individual research projects.
If you have any questions you can fill in the form or mail us directly: firstname.lastname@example.org.
This online conference links scientific and clinical experts in the prevention, diagnosis, prediction, and management of necrotizing enterocolitis (NEC) as well as parents to talk about their experiences. The faculty will be international and include recognised experts in their fields. The presentations will consist of state-of-the-art lectures covering the basic science of underlying mechanisms, along with clinical aspects of prevention and management.
A dysbiosis in gut microbes has been linked to a wide range of chronic diseases. An interesting perspective paper in Science "Modulating gut microbes" describes the current strategies to target gut microbes.
The 6th edition of the Dutch Bioinformatics & Systems Biology (BioSB) conference will be online and organised on October 27-28, 2020.
Mohammed Ghiboub, together with Dr Bruno Sovran and Prof. Wouter de Jonge, published a very nice review on nutritional interventions targeting Tryptophan (Trp) metabolism and Aryl Hydrocarbon-Receptor (AhR) signaling (Nutrients 2020, 12(9), 2846; https://doi.org/10.3390/nu12092846).
Recently, a cutting-edge technology was installed at AMC to define the volatiles emitted from the feces of healthy donors and patients with gastrointestinal disease. Owlstone Medical, one of the GROWTH collaborators, has developed this technology and is worldwide one of the pioneering companies in breath biopsy applications in early disease detection and precision medicine.